Comparative Pharmacology
Head-to-head clinical analysis: INTRALIPID 30 versus LIQREV.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INTRALIPID 30 versus LIQREV.
INTRALIPID 30% vs LIQREV
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Intralipid is a source of calories and essential fatty acids. It provides a mixture of triglycerides, primarily long-chain fatty acids, which are metabolized to generate energy and serve as substrates for lipid membrane synthesis. It also prevents essential fatty acid deficiency.
Liqrev (sildenafil) is a phosphodiesterase-5 (PDE5) inhibitor. It enhances the effect of nitric oxide by inhibiting PDE5, which degrades cGMP in the corpus cavernosum, leading to increased cGMP levels and smooth muscle relaxation, thereby facilitating penile erection.
Intralipid 30% is administered intravenously as a component of parenteral nutrition. The typical adult dose is 1-2 g/kg/day of fat, not to exceed 60% of total calories. The infusion rate should not exceed 0.11 g/kg/hour (equivalent to 0.37 mL/kg/hour of 30% emulsion).
LIQREV (ivermectin) 200 mcg/kg orally once, taken on an empty stomach with water.
None Documented
None Documented
The elimination half-life of Intralipid 30% triglycerides is approximately 30-45 minutes under steady-state conditions in patients with normal lipid metabolism, though this may extend to several hours in critically ill patients or those with impaired clearance. Clinically, the half-life is dose- and infusion-rate-dependent; for continuous infusion, clearance rates are typically 0.1-0.3 g/kg/h, with complete clearance of infused lipids within 4-6 hours after cessation of infusion in healthy adults.
Terminal elimination half-life is 12–15 hours in healthy adults; prolonged to 24–30 hours in moderate renal impairment (CrCl <50 mL/min).
Intralipid 30% is a fat emulsion containing soybean oil, egg lecithin, and glycerin, providing essential fatty acids and triglycerides. The lipid particles are metabolized similarly to endogenous chylomicrons, primarily cleared from the bloodstream by lipoprotein lipase in peripheral tissues, releasing free fatty acids which are then utilized or stored. Less than 10% of the administered dose is excreted unchanged in urine; the majority of the lipid components are oxidized to CO2 and water or incorporated into body stores. Biliary/fecal excretion is negligible for the intact emulsion but metabolites may be excreted in bile or feces in small amounts.
Primarily renal (70% as unchanged drug, 15% as glucuronide conjugate); 10% biliary/fecal.
Category C
Category C
Intravenous Fat Emulsion
Intravenous Fat Emulsion